1
项与 Dendritic Killer Cell (DKC)(FullHope Biomedical) 相关的临床试验Phase I Clinical Trial of Autologous Dendritic Killer Cell-based Immunotherapy for Solid Tumors
The primary objective of this study is to evaluate the safety of autologous dendritic killer cell (DKC) in patients with metastatic solid tumor and to evaluate the maximum tolerated dose (MTD) of DKC. The primary endpoint of safety evaluation includes physical examination, assessment of vital sign, laboratory test, concomitant medication, and adverse event (AE). The secondary endpoints regarding efficacy includes the generation of tumor specific immune response by detecting CD3+ CD8+ CD69+ IFN-gamma+ T cells, and the improvement of quality of life
100 项与 Dendritic Killer Cell (DKC)(FullHope Biomedical) 相关的临床结果
100 项与 Dendritic Killer Cell (DKC)(FullHope Biomedical) 相关的转化医学
100 项与 Dendritic Killer Cell (DKC)(FullHope Biomedical) 相关的专利(医药)
100 项与 Dendritic Killer Cell (DKC)(FullHope Biomedical) 相关的药物交易